RUA Life Sciences (AOHA) Stock Price & Analysis
AOHA Stock Chart & Stats
- Day’s Range
- EUR 0.28 - EUR 0.30
- 52-Week Range
- EUR 0.09 - EUR 0.35
- Previous Close
- EUR 0.28
- Volume
- 0
- Average Volume (3M)
- 18
- Market Cap
- EUR 21.15M
- Enterprise Value
- EUR 6.08M
- Total Cash (Recent Filing)
- EUR 3.25M
- Total Debt (Recent Filing)
- EUR 794.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.55
- Next Earnings
- Jul 19, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Specialized Biomaterials Platform
The company operates across biomaterials supply, product development support, and manufacturing for medical-device customers. This integrated capability can deepen customer relationships and support recurring demand when development programs progress into regulated commercial production.
Revenue Scale And Gross Margin
Revenue has expanded substantially over the reported period while gross margin remains strong, indicating that the business can retain meaningful value from its specialized products and services. If maintained, this gross-profit base provides capacity to fund development and move toward operating profitability.
Conservative Balance Sheet
Low leverage and a substantial equity base provide financial flexibility relative to a highly indebted structure. This should reduce interest and refinancing pressure, preserve room for investment in biomaterials programs, and improve resilience while the company works toward stable earnings.
Bears Say
Operating Losses Persist
Operating profitability has not yet been established, so strong gross margin is not currently translating into sustainable earnings after operating costs. Continued EBIT losses could restrict internal funding, delay shareholder returns, and leave results sensitive to the timing of customer-program progress.
Negative Cash Generation
The business remains cash-consuming rather than self-funding, even though annual burn has improved materially from earlier periods. Persistent negative operating and free cash flow can increase reliance on external capital and constrain the pace of product development or manufacturing expansion.
Returns Remain Unsettled
Slightly negative return on equity and a modest net loss show that the company is not yet generating dependable returns on its capital base. Until earnings stabilize, the healthy balance sheet may support continuity but cannot by itself demonstrate an attractive or durable economic return.
RUA Life Sciences News
AOHA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
What is RUA Life Sciences’s market cap?
When is RUA Life Sciences’s upcoming earnings report date?
How were RUA Life Sciences’s earnings last quarter?
Is RUA Life Sciences overvalued?
Does RUA Life Sciences pay dividends?
What is RUA Life Sciences’s EPS estimate?
How many shares outstanding does RUA Life Sciences have?
What happened to RUA Life Sciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of RUA Life Sciences?
What is the TipRanks Smart Score and how is it calculated?
Company Description
RUA Life Sciences
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- William Donald Brown
- Employees
- 59
- Website
- rualifesciences.com
- Address
- 2 Drummond Crescent, Irvine, SC, KA11 5AN, GB
RUA Life Sciences (AOHA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 5 | 2 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 12 | 0 | 0 |